Investing.com - Financial Markets Worldwide

Orient Europharma Co Ltd (4120)

TPEX
Currency in TWD
52.30
0.00(0.00%)
Closed·
4120 Scorecard
Full Analysis
Trading at a low Price / Book multiple
4120 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Unlock Value
Day's Range
52.1052.50
52 wk Range
40.0560.70
Key Statistics
Edit
Bid/Ask
43.75 / 44.00
Prev. Close
48.4
Open
52.5
Day's Range
52.1-52.5
52 wk Range
40.05-60.7
Volume
46.85K
Average Volume (3m)
161.94K
1-Year Change
9.76%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
4120 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Technical Analysis
Strong Sell
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Unlock All 4
Prominent player in the Pharmaceuticals industry
Unlock InvestingPro

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Orient Europharma Co Ltd Company Profile

Orient EuroPharma Co., Ltd., a pharmaceutical company, develops and manufactures drugs worldwide. Its prescription medicines include cardiovascular, metabolism, neurology, obstetrics and gynecology, respiratory, andrology, immunology, antibiotic, and anti-cancer drugs. The company also provides nutrition and baby care products, such as milk and nutritional supplements under the Karihome, Babecare, and Ostricare brands; and healthcare supplements, such as thermal water for the treatment of oral and periodontal diseases under the Buccotherm name. In addition, the company offers essences, creams, lotions, eye creams, facial treatment toners, and skin repairing essences under the AGLab name; skincare oils, body lotions, and dry skin gels under the Bio-Oil name; and children skincare products under the Mister Baby brand, as well as operates ISISPHARMA, a dermatology laboratory specialized in the development and distribution of dermo-cosmetic products. Further, it engages in the research and development of Multikine, an immunotherapy drug for head and neck cancer, which is in Phase III clinical study; NC-6004, a platinum-based micelle chemotherapeutic drug that is in Phase III clinical study; ASC-J9, a molecular chemical entity drug that has completed Phase IIb clinical study for androgen receptor degradation; and 2ccPA, a derivative of phospholipid to patients with symptomatic osteoarthritis of the knee, which is in Phase I clinical trail. Orient EuroPharma Co., Ltd. was founded in 1982 and is based in Taipei, Taiwan.

Industry
Food & Tobacco
Sector
Consumer Non-Cyclicals
Employees
339
Market
Taiwan

Compare 4120 to Peers and Sector

Metrics to compare
4120
Peers
Sector
Relationship
P/E Ratio
−14.0x−14.6x−0.6x
PEG Ratio
0.040.100.00
Price/Book
0.7x2.2x2.6x
Price / LTM Sales
1.0x5.5x3.3x
Upside (Analyst Target)
-0.0%39.1%
Fair Value Upside
Unlock−2.5%4.5%Unlock

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS -3.72%
Dividend Yield
1.88%
Industry Median 3.69%
Annualised payout
1.00
Paid annually
5-Years Growth
-
Growth Streak
Unlock

Earnings

Latest Release
Aug 12, 2025
EPS / Forecast
-0.53 / --
Revenue / Forecast
1.13B / --
EPS Revisions
a
a
Unlock
Last 90 days

4120 Income Statement

FAQ

What Stock Exchange Does Orient Europharma Trade On?

Orient Europharma is listed and trades on the Taipei Exchange stock exchange.

What Is the Stock Symbol for Orient Europharma?

The stock symbol for Orient Europharma is "4120."

What Is the Orient Europharma Market Cap?

As of today, Orient Europharma market cap is 4.54B.

What Is Orient Europharma's Earnings Per Share (TTM)?

The Orient Europharma EPS (TTM) is -3.72.

From a Technical Analysis Perspective, Is 4120 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Orient Europharma Stock Split?

Orient Europharma has split 8 times.

How Many Employees Does Orient Europharma Have?

Orient Europharma has 339 employees.

What is the current trading status of Orient Europharma (4120)?

As of 19 Aug 2025, Orient Europharma (4120) is trading at a price of 52.30, with a previous close of 48.40. The stock has fluctuated within a day range of 52.10 to 52.50, while its 52-week range spans from 40.05 to 60.70.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.